Evidence map›Paper›PMID 28573235›Full record

ArticleAfrican journal of traditional, complementary, and alternative medicines : AJTCAM2017

O J Nieto-Yañez, A A Resendiz-Albor, P A Ruiz-Hurtado, N Rivera-Yañez, M Rodriguez-Canales, M Rodriguez-Sosa, I Juarez-Avelar, M G Rodriguez-Lopez, M M Canales-Martinez, M A Rodriguez-Monroy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African journal of traditional, complementary, and alternative medicines : AJTCAM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Lignans fromLife (Basel, Switzerland) · 2021
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

O J Nieto-YañezLaboratorio de Inmunidad de Mucosas. Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, del Instituto Politécnico Nacional. Av. Plan de San Luis S/N, Colonia Casco de Santo Tomas, Miguel Hidalgo, CP. 11350. Ciudad de México, D.F.
A A Resendiz-AlborLaboratorio de Inmunidad de Mucosas. Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina, del Instituto Politécnico Nacional. Av. Plan de San Luis S/N, Colonia Casco de Santo Tomas, Miguel Hidalgo, CP. 11350. Ciudad de México, D.F.
P A Ruiz-HurtadoLab. Inmunobiología (L-321). UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
N Rivera-YañezLab. Inmunobiología (L-321). UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
M Rodriguez-CanalesLab. Inmunobiología (L-321). UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
M Rodriguez-SosaUnidad de Biomedicina. UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
I Juarez-AvelarUnidad de Biomedicina. UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
M G Rodriguez-LopezLab. Farmacognosia, UBIPRO. UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
M M Canales-MartinezLab. Farmacognosia, UBIPRO. UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
M A Rodriguez-MonroyLab. Inmunobiología (L-321). UNAM FES Iztacala. Avenida de los Barrios Número 1, Colonia Los Reyes Iztacala, Tlalnepantla, Estado de México, C.P. 54090.
Autonomous University of Tlaxcala · MXInstituto Politécnico Nacional · MXUniversidad Latina de América · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCutaneous leishmaniasis lacks effective and well-tolerated treatments. The current therapies mainly rely on antimonial drugs that are inadequate because of their poor efficacy. Traditional medicine offers a complementary alternative for the treatment of various diseases. Additionally, several plants have shown success as anti-leishmanial agents. Therefore, we sought to evaluate the MATERIALS AND

methodsMethanolic extract of

resultsWe determined of LC

conclusionBased on the above data, it was concluded that MEBA is a good candidate in the search for new anti-leishmanial agents.

Indexed as

Leishmania mexicanaPhytotherapyAnimalsBurseraFemaleInterferon-gammaLeishmaniasis, CutaneousMedicine, TraditionalMice, Inbred BALB CPlant BarkPlant ExtractsPodophyllotoxinTumor Necrosis Factor-alphaInterferon-gammaPlant ExtractsPodophyllotoxinTumor Necrosis Factor-alphacutaneous leishmaniasisLeishmaniatraditional medicine

Identifiers

PMID28573235
PMCPMC5446443
OpenAlexW2588045392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.